Lonza to double production of Covid-19 vaccine at Swiss plant
Lonza has struggled to recruit enough workers to join its Visp plant, which now has three production lines set up and plans three more by early 2022.
Keystone / Olivier Maire
Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort to boost the global supply of doses.
This content was published on
2 minutes
swissinfo.ch/SRF/gw
Español
es
Lonza duplicará la producción de la vacuna COVID-19 en su planta suiza
The new production lines will be added gradually to three existing lines and be fully operational by early 2022, Lonza said on Thursday. The two companies signed a ten-year contract in 2020 that enables Lonza to make a drug substance for the mRNA vaccine at its plant for the global market outside the United States.
In a separate press release, Moderna said it planned to increase the overall supply to up to three billion doses by 2022. The firm calculates there will be greater demand for its vaccine as the need for booster shots is likely to grow starting next year.
The announcement comes as Lonza struggles to recruit enough workers to join its Visp plant. Biotech specialists are currently in high demand worldwide as a result of the pandemic, Swiss public television, SRF, reported, adding that the interior ministry is now actively helping Lonza to find specialists from inside the federal administration and universities, including the federal technology institutes ETH Zurich and the EPFL in Lausanne.
Lonza has reportedly recruited temporary staff from food giant Nestlé with help from the Swiss government. Moderna has blamed projected delays in shipments of the vaccine to markets such as the UK and Canada on production bottlenecks, according to Reuters.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Is artificial intelligence an advantage or a disadvantage for workers?
What is your experience with AI at work? Have you already used it? Has it helped you work better? Or has it caused you more stress, more work or caused you to lose your job? Tell us about your experiences!
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
Swiss firm Lonza to help produce anti-Covid nasal spray in the US
This content was published on
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine.
Switzerland mulls future European coordination on medical supplies
This content was published on
“The pandemic has shown us that we are very dependent, maybe too much so, on other markets,” Swiss President Guy Parmelin has said.
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.